Annual SG&A
$105.74 M
-$6.71 M-5.97%
31 December 2023
Summary:
Rigel Pharmaceuticals annual selling, general & administrative expenses is currently $105.74 million, with the most recent change of -$6.71 million (-5.97%) on 31 December 2023. During the last 3 years, it has risen by +$29.14 million (+38.05%). RIGL annual SG&A is now -5.97% below its all-time high of $112.45 million, reached on 31 December 2022.RIGL Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$27.04 M
-$1.00 M-3.58%
30 September 2024
Summary:
Rigel Pharmaceuticals quarterly selling, general & administrative expenses is currently $27.04 million, with the most recent change of -$1.00 million (-3.58%) on 30 September 2024. Over the past year, it has increased by +$2.19 million (+8.80%). RIGL quarterly SG&A is now -15.94% below its all-time high of $32.17 million, reached on 31 December 2022.RIGL Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$5.64 B
+$3.88 M+0.07%
30 September 2024
Summary:
Rigel Pharmaceuticals TTM selling, general & administrative expenses is currently -$5.64 billion, with the most recent change of +$3.88 million (+0.07%) on 30 September 2024. Over the past year, it has dropped by -$5.76 billion (-5182.32%). RIGL TTM SG&A is now -10356.99% below its all-time high of $112.78 million, reached on 31 March 2023.RIGL TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RIGL Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -6.0% | +8.8% | -5182.3% |
| 3 y3 years | +38.0% | +18.2% | -6428.4% |
| 5 y5 years | +51.0% | +49.2% | -7369.6% |
RIGL Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -6.0% | +38.0% | -15.9% | +18.2% | -9.5% | +0.1% |
| 5 y | 5 years | -6.0% | +51.0% | -15.9% | +55.1% | -14.2% | +0.1% |
| alltime | all time | -6.0% | +2575.6% | -15.9% | +1299.0% | <-9999.0% | +0.1% |
Rigel Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $27.04 M(-3.6%) | $110.39 M(+2.0%) |
| June 2024 | - | $28.05 M(-1.4%) | $108.20 M(+1.6%) |
| Mar 2024 | - | $28.45 M(+6.0%) | $106.46 M(+0.7%) |
| Dec 2023 | $105.74 M(-6.0%) | $26.85 M(+8.0%) | $105.74 M(-4.8%) |
| Sept 2023 | - | $24.86 M(-5.5%) | $111.06 M(-0.9%) |
| June 2023 | - | $26.31 M(-5.1%) | $112.10 M(-0.6%) |
| Mar 2023 | - | $27.73 M(-13.8%) | $112.78 M(+0.3%) |
| Dec 2022 | $112.45 M(+22.4%) | $32.17 M(+24.2%) | $112.45 M(+7.3%) |
| Sept 2022 | - | $25.90 M(-4.0%) | $104.79 M(+3.0%) |
| June 2022 | - | $26.98 M(-1.5%) | $101.77 M(+4.7%) |
| Mar 2022 | - | $27.40 M(+11.8%) | $97.17 M(+5.7%) |
| Dec 2021 | $91.89 M(+20.0%) | $24.52 M(+7.2%) | $91.89 M(+3.0%) |
| Sept 2021 | - | $22.88 M(+2.2%) | $89.19 M(+6.5%) |
| June 2021 | - | $22.38 M(+1.2%) | $83.75 M(+4.3%) |
| Mar 2021 | - | $22.12 M(+1.4%) | $80.29 M(+4.8%) |
| Dec 2020 | $76.60 M(+2.7%) | $21.82 M(+25.2%) | $76.60 M(+4.8%) |
| Sept 2020 | - | $17.43 M(-7.9%) | $73.09 M(-0.9%) |
| June 2020 | - | $18.92 M(+2.7%) | $73.78 M(+1.0%) |
| Mar 2020 | - | $18.43 M(+0.6%) | $73.07 M(-2.0%) |
| Dec 2019 | $74.59 M(+6.6%) | $18.31 M(+1.1%) | $74.59 M(-3.9%) |
| Sept 2019 | - | $18.12 M(-0.5%) | $77.65 M(+0.1%) |
| June 2019 | - | $18.21 M(-8.7%) | $77.59 M(+1.5%) |
| Mar 2019 | - | $19.95 M(-6.7%) | $76.46 M(+9.2%) |
| Dec 2018 | $70.00 M(+85.0%) | $21.37 M(+18.3%) | $70.00 M(+10.6%) |
| Sept 2018 | - | $18.07 M(+5.8%) | $63.29 M(+19.0%) |
| June 2018 | - | $17.07 M(+26.5%) | $53.16 M(+21.1%) |
| Mar 2018 | - | $13.49 M(-7.9%) | $43.91 M(+16.1%) |
| Dec 2017 | $37.83 M(+80.9%) | $14.65 M(+84.4%) | $37.83 M(+24.7%) |
| Sept 2017 | - | $7.95 M(+1.6%) | $30.33 M(+12.6%) |
| June 2017 | - | $7.82 M(+5.5%) | $26.94 M(+12.7%) |
| Mar 2017 | - | $7.41 M(+3.6%) | $23.89 M(+14.3%) |
| Dec 2016 | $20.91 M(+17.4%) | $7.15 M(+56.9%) | $20.91 M(+13.2%) |
| Sept 2016 | - | $4.56 M(-4.5%) | $18.48 M(+1.5%) |
| June 2016 | - | $4.77 M(+7.9%) | $18.19 M(+3.9%) |
| Mar 2016 | - | $4.42 M(-6.3%) | $17.52 M(-1.7%) |
| Dec 2015 | $17.81 M(-44.0%) | $4.72 M(+10.4%) | $17.81 M(-38.8%) |
| Sept 2015 | - | $4.28 M(+4.3%) | $29.10 M(-2.1%) |
| June 2015 | - | $4.10 M(-13.1%) | $29.71 M(-4.2%) |
| Mar 2015 | - | $4.72 M(-70.5%) | $31.00 M(-2.5%) |
| Dec 2014 | $31.80 M(+62.2%) | $16.00 M(+227.4%) | $31.80 M(+55.5%) |
| Sept 2014 | - | $4.89 M(-9.3%) | $20.45 M(+1.0%) |
| June 2014 | - | $5.39 M(-2.2%) | $20.23 M(+2.5%) |
| Mar 2014 | - | $5.52 M(+18.7%) | $19.73 M(+0.6%) |
| Dec 2013 | $19.61 M(-14.2%) | $4.65 M(-0.6%) | $19.61 M(-5.8%) |
| Sept 2013 | - | $4.68 M(-4.4%) | $20.82 M(-3.3%) |
| June 2013 | - | $4.89 M(-9.3%) | $21.52 M(-2.6%) |
| Mar 2013 | - | $5.39 M(-7.8%) | $22.09 M(-3.3%) |
| Dec 2012 | $22.85 M | $5.85 M(+8.7%) | $22.85 M(-1.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | $5.38 M(-1.4%) | $23.09 M(+1.3%) |
| June 2012 | - | $5.46 M(-11.3%) | $22.79 M(+2.8%) |
| Mar 2012 | - | $6.16 M(+1.1%) | $22.17 M(+1.8%) |
| Dec 2011 | $21.77 M(-13.9%) | $6.09 M(+19.9%) | $21.77 M(+0.8%) |
| Sept 2011 | - | $5.08 M(+4.9%) | $21.59 M(-2.0%) |
| June 2011 | - | $4.84 M(-15.8%) | $22.04 M(-3.6%) |
| Mar 2011 | - | $5.75 M(-2.7%) | $22.86 M(-9.6%) |
| Dec 2010 | $25.29 M(+21.0%) | $5.91 M(+6.9%) | $25.29 M(+0.9%) |
| Sept 2010 | - | $5.53 M(-2.4%) | $25.06 M(-0.2%) |
| June 2010 | - | $5.66 M(-30.8%) | $25.10 M(+2.5%) |
| Mar 2010 | - | $8.19 M(+44.2%) | $24.49 M(+17.1%) |
| Dec 2009 | $20.90 M(-22.7%) | $5.68 M(+1.9%) | $20.90 M(+0.3%) |
| Sept 2009 | - | $5.57 M(+10.4%) | $20.83 M(-8.3%) |
| June 2009 | - | $5.05 M(+9.7%) | $22.71 M(-7.4%) |
| Mar 2009 | - | $4.60 M(-17.9%) | $24.52 M(-9.3%) |
| Dec 2008 | $27.04 M(+24.3%) | $5.61 M(-24.7%) | $27.04 M(-2.5%) |
| Sept 2008 | - | $7.45 M(+8.6%) | $27.73 M(+9.5%) |
| June 2008 | - | $6.86 M(-3.7%) | $25.34 M(+6.2%) |
| Mar 2008 | - | $7.13 M(+13.1%) | $23.85 M(+9.6%) |
| Dec 2007 | $21.76 M(+11.3%) | $6.30 M(+24.6%) | $21.76 M(+6.2%) |
| Sept 2007 | - | $5.05 M(-5.9%) | $20.49 M(+1.2%) |
| June 2007 | - | $5.37 M(+6.6%) | $20.24 M(+3.3%) |
| Mar 2007 | - | $5.04 M(+0.4%) | $19.59 M(+0.2%) |
| Dec 2006 | $19.55 M(+57.6%) | $5.02 M(+4.5%) | $19.55 M(+13.3%) |
| Sept 2006 | - | $4.80 M(+1.7%) | $17.26 M(+9.0%) |
| June 2006 | - | $4.72 M(-5.6%) | $15.84 M(+8.9%) |
| Mar 2006 | - | $5.00 M(+83.7%) | $14.54 M(+17.2%) |
| Dec 2005 | $12.41 M(-5.1%) | $2.72 M(-19.5%) | $12.41 M(-7.3%) |
| Sept 2005 | - | $3.38 M(-1.3%) | $13.39 M(-2.4%) |
| June 2005 | - | $3.43 M(+19.3%) | $13.72 M(+5.2%) |
| Mar 2005 | - | $2.87 M(-22.5%) | $13.04 M(-0.3%) |
| Dec 2004 | $13.08 M(+53.5%) | $3.71 M(-0.1%) | $13.08 M(+11.9%) |
| Sept 2004 | - | $3.71 M(+35.1%) | $11.68 M(+15.3%) |
| June 2004 | - | $2.75 M(-5.7%) | $10.13 M(+7.8%) |
| Mar 2004 | - | $2.91 M(+26.0%) | $9.40 M(+10.3%) |
| Dec 2003 | $8.52 M(-9.9%) | $2.31 M(+7.0%) | $8.52 M(+2.3%) |
| Sept 2003 | - | $2.16 M(+7.4%) | $8.33 M(+0.4%) |
| June 2003 | - | $2.01 M(-1.1%) | $8.29 M(-8.3%) |
| Mar 2003 | - | $2.03 M(-4.0%) | $9.04 M(-4.3%) |
| Dec 2002 | $9.45 M(+18.9%) | $2.12 M(-0.5%) | $9.45 M(+0.6%) |
| Sept 2002 | - | $2.13 M(-22.9%) | $9.40 M(+1.5%) |
| June 2002 | - | $2.76 M(+13.0%) | $9.26 M(+9.8%) |
| Mar 2002 | - | $2.44 M(+18.4%) | $8.43 M(+6.1%) |
| Dec 2001 | $7.95 M(+18.9%) | $2.06 M(+3.7%) | $7.95 M(+35.1%) |
| Sept 2001 | - | $1.99 M(+3.0%) | $5.88 M(+51.1%) |
| June 2001 | - | $1.93 M(-1.4%) | $3.89 M(+98.6%) |
| Mar 2001 | - | $1.96 M | $1.96 M |
| Dec 2000 | $6.69 M(+69.3%) | - | - |
| Dec 1999 | $3.95 M | - | - |
FAQ
- What is Rigel Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals annual SG&A year-on-year change?
- What is Rigel Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals quarterly SG&A year-on-year change?
- What is Rigel Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Rigel Pharmaceuticals?
- What is Rigel Pharmaceuticals TTM SG&A year-on-year change?
What is Rigel Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of RIGL is $105.74 M
What is the all time high annual SG&A for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high annual selling, general & administrative expenses is $112.45 M
What is Rigel Pharmaceuticals annual SG&A year-on-year change?
Over the past year, RIGL annual selling, general & administrative expenses has changed by -$6.71 M (-5.97%)
What is Rigel Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of RIGL is $27.04 M
What is the all time high quarterly SG&A for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $32.17 M
What is Rigel Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, RIGL quarterly selling, general & administrative expenses has changed by +$2.19 M (+8.80%)
What is Rigel Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of RIGL is -$5.64 B
What is the all time high TTM SG&A for Rigel Pharmaceuticals?
Rigel Pharmaceuticals all-time high TTM selling, general & administrative expenses is $112.78 M
What is Rigel Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, RIGL TTM selling, general & administrative expenses has changed by -$5.76 B (-5182.32%)